Compare EHAB & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHAB | AGMB |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 690.9M | 677.9M |
| IPO Year | 2020 | N/A |
| Metric | EHAB | AGMB |
|---|---|---|
| Price | $13.61 | $14.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $13.84 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.5M | 97.7K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,060,000,000.00 | N/A |
| Revenue This Year | $6.23 | N/A |
| Revenue Next Year | $4.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.44 | N/A |
| 52 Week Low | $6.47 | $13.20 |
| 52 Week High | $13.66 | $17.45 |
| Indicator | EHAB | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 79.57 | 46.09 |
| Support Level | $10.79 | $13.43 |
| Resistance Level | $13.65 | $16.16 |
| Average True Range (ATR) | 0.03 | 1.18 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 55.00 | 30.57 |
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.